Visage receives FDA clearance for thin client upgrade
Visage Imaging, a wholly owned subsidiary of Mercury Computer Systems, has obtained 510(k) clearance from the FDA to market its latest thin client product release, Visage CS 3.1.
New enhancements include cardiac and other tools, as well as new optional neuroradiology and oncology applications. The neuro option facilitates brain perfusion analysis in CT and MRI imaging, while the oncology option provides tools for analyzing, documenting and comparing lesions for multiple modalities, including standardized update value-based analysis for PET/CT.
Hartmut Schirmacher, director of product management for Visage, said that Visage CS offers “far superior performance across the board, especially when viewing and processing large data volumes. Furthermore, Visage CS 3.1 will affordably allow for broader access to state-of-the-art applications throughout the enterprise.”
In addition to the new application options, Visage CS 3.1 features new and streamlined measurement and post processing tools such as advanced 3D segmentation, ROI-based analysis and time-value curves, and improved editing of cardiac LV models, according to the Carlsbad, Calif.-based company.
New enhancements include cardiac and other tools, as well as new optional neuroradiology and oncology applications. The neuro option facilitates brain perfusion analysis in CT and MRI imaging, while the oncology option provides tools for analyzing, documenting and comparing lesions for multiple modalities, including standardized update value-based analysis for PET/CT.
Hartmut Schirmacher, director of product management for Visage, said that Visage CS offers “far superior performance across the board, especially when viewing and processing large data volumes. Furthermore, Visage CS 3.1 will affordably allow for broader access to state-of-the-art applications throughout the enterprise.”
In addition to the new application options, Visage CS 3.1 features new and streamlined measurement and post processing tools such as advanced 3D segmentation, ROI-based analysis and time-value curves, and improved editing of cardiac LV models, according to the Carlsbad, Calif.-based company.